A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-DAILY RO6811135 IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2016
Price : $35 *
At a glance
- Drugs RG 7697 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 05 Dec 2013 Planned end date changed from 1 Sep 2014 to 31 Dec 2013 as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.